Premium Nahrungsergänzungsmittel | artgerecht

IBS Biomarkers – Diagnosis and Significance

Irritable bowel syndrome biomarkers are measurable biological parameters used to diagnose and classify IBS. They help distinguish IBS from other gastrointestinal disorders.

Regular tips about health Regular tips about health

Things worth knowing about "Irritable Bowel Syndrome Biomarkers"

Irritable bowel syndrome biomarkers are measurable biological parameters used to diagnose and classify IBS. They help distinguish IBS from other gastrointestinal disorders.

What Are Irritable Bowel Syndrome Biomarkers?

Irritable bowel syndrome (IBS) biomarkers are biological measurements found in blood, stool, or tissue that can provide evidence for the presence or subtype of IBS. Because IBS is a functional gastrointestinal disorder -- meaning that standard imaging and endoscopic procedures often reveal no visible abnormalities -- biomarkers are increasingly important for achieving a more objective and reliable diagnosis.

Background: Irritable Bowel Syndrome

Irritable bowel syndrome is a common, chronic gastrointestinal condition characterized by abdominal pain, bloating, and altered bowel habits including diarrhea, constipation, or a combination of both. Its exact cause is multifactorial, involving disturbances of the gut-brain axis, altered gut motility, low-grade intestinal inflammation, and changes in the gut microbiome. Diagnosis is currently based primarily on the Rome IV criteria (clinical diagnostic criteria), as no single definitive biomarker yet exists.

Key Biomarkers in Irritable Bowel Syndrome

Stool-Based Inflammatory Biomarkers

Stool biomarkers are used to differentiate IBS from inflammatory bowel diseases such as Crohn's disease or ulcerative colitis:

Calprotectin: A protein released by white blood cells (neutrophils). Elevated levels suggest inflammatory bowel disease, while normal levels support a diagnosis of IBS.
Lactoferrin: Similar to calprotectin, this marker indicates intestinal inflammation and helps distinguish organic bowel disease from IBS.
Lysozyme: Another inflammatory marker being studied in the context of gastrointestinal diseases.

Blood-Based Biomarkers

Several blood parameters are being investigated for their usefulness as IBS biomarkers:

CRP (C-reactive protein): A general marker of inflammation. In IBS, CRP is usually within the normal range; elevated levels may point to other conditions.
Serotonin (5-HT): Approximately 95% of the body's serotonin is produced in the gut. Altered serotonin levels in the blood or intestinal tissue have been observed in IBS patients and are linked to motility disturbances.
Anti-CdtB and anti-vinculin antibodies: These antibodies develop following certain gastrointestinal infections and have been identified as potential biomarkers for post-infectious IBS, helping to identify specific subtypes.

Microbiome-Based Biomarkers

The gut microbiome -- the entire community of microorganisms living in the intestine -- frequently shows compositional changes in people with IBS. Specific bacterial profiles or ratios of bacterial strains are being explored as potential biomarkers, although these are not yet standardized for routine clinical use.

Intestinal Permeability Markers

Increased intestinal permeability (sometimes referred to as leaky gut) is discussed as a possible mechanism in IBS. Markers such as zonulin or intestinal fatty acid-binding protein (I-FABP) are used in research studies to assess gut barrier function.

Genetic and Molecular Biomarkers

Research is exploring genetic variants associated with IBS, including polymorphisms in the serotonin transporter gene (SERT/SLC6A4) and genes involved in gut-brain communication. These markers are not yet established in routine diagnostic practice.

Diagnostic Significance

No single IBS biomarker is currently recognized as a standalone diagnostic criterion. Instead, biomarkers are used as complementary tools to:

exclude organic gastrointestinal diseases
differentiate IBS subtypes (e.g., diarrhea-predominant, constipation-predominant, or mixed type)
assess disease severity
monitor treatment response

Future Outlook

Research into IBS biomarkers is an active and growing field. The goal is to establish reliable, non-invasive biomarkers that enable faster and more precise diagnosis and support the development of individualized treatment strategies. Multi-marker panels combining several biomarkers are showing promising results in recent studies.

References

Lacy BE et al. - Bowel Disorders. Gastroenterology, 2016; 150(6):1393-1407. (Rome IV Criteria)
Tibble JA, Bjarnason I. - Fecal calprotectin as an index of intestinal inflammation. Drugs, 2001; 61(9):1233-1242.
Pimentel M et al. - ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology, 2020; 115(2):165-178.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category